pembrolizumab,lenvatinib
merck,eisai
[]
a follow-up analysis of the phase 3 leap-002 study in patients with advanced #hcc showed similar health-related quality of life scores for patients given the combination of #pembrolizumab and #lenvatinib or lenvatinib and placebo. #gi23 | 
Oncology news and insights from leading researchers and cancer centers.